



ELSEVIER

Critical Reviews in Oncology/Hematology xxx (2013) xxx–xxx

CRITICAL REVIEWS IN

*Oncology
Hematology*

Incorporating Geriatric Oncology

www.elsevier.com/locate/critrevonc

Biomarkers in bladder cancer: Translational and clinical implications

Liang Cheng^{a,b,*}, Darrell D. Davison^a, Julia Adams^a, Antonio Lopez-Beltran^c, Lisha Wang^{a,d},
Rodolfo Montironi^e, Shaobo Zhang^a

^a Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA

^b Department of Urology, Indiana University School of Medicine, Indianapolis, IN, USA

^c Department of Pathology, Cordoba University, Cordoba, Spain

^d Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China

^e Institute of Pathological Anatomy and Histopathology, School of Medicine, Polytechnic University of the Marche Region (Ancona), United Hospitals, Ancona, Italy

Accepted 13 August 2013

Contents

1. Introduction.....	00
2. Proliferation markers (PCNA, Ki67, and MIB1).....	00
3. Apoptosis markers.....	00
4. Tumor suppressor genes.....	00
4.1. TP53 and cell cycle regulators.....	00
4.1.1. TP53.....	00
4.1.2. p21 (WAF1/CIP1/CDKN1A).....	00
4.1.3. p16 (INK4/CDKN2A/MTS1).....	00
4.1.4. p15 (INK4B/CDKN2B).....	00
4.1.5. p27 (KIP1/CDKN1B).....	00
4.2. Retinoblastoma gene.....	00
4.3. TSC1.....	00
4.4. PTEN.....	00
4.5. FHIT.....	00
4.6. p63.....	00
4.7. NF1.....	00
4.8. FEZ1/LZTS1.....	00
5. Growth factors and receptors.....	00
5.1. FGFR3.....	00
5.2. EGFR/ERBB1.....	00
5.3. VEGF.....	00
5.4. AFGF/FGF1.....	00
5.5. BFGF/FGF2.....	00
5.6. TGFB1.....	00
5.7. EPHA2.....	00
5.8. ERBB2 (HER2).....	00

* Corresponding author at: Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, 350 West 11th Street, Indianapolis, IN 46202, USA. Tel.: +1 317 491 6442; fax: +1 317 491 6419.

E-mail address: liang_cheng@yahoo.com (L. Cheng).

6.	Oncogenes	00
6.1.	HRAS	00
6.2.	MDM2	00
6.3.	MYC	00
6.4.	Cyclin D1 and D3	00
6.5.	PAX5	00
6.6.	IMP3	00
7.	Hormone receptors	00
7.1.	Androgen receptor (AR)	00
7.2.	Estrogen receptor (ER)	00
7.3.	Progesterone receptor (PR)	00
8.	Cell adhesion molecules	00
8.1.	E-cadherin and integrins	00
8.2.	CD44	00
8.3.	CD24	00
8.4.	Tetranectin	00
9.	Vessel density	00
9.1.	Microvessel density	00
9.2.	Lymph vessel density	00
10.	Telomerase (TERT)	00
11.	Miscellaneous markers	00
11.1.	Hyaluronic acid (HA) and hyaluronoglucosaminidase 1 (HYAL1)	00
11.2.	Microtubule-associated proteins	00
11.3.	E2F transcription factor 1	00
11.4.	Mammary serine protease inhibitor (maspin)	00
11.5.	Multidrug resistance proteins	00
11.6.	Cyclooxygenase 2	00
11.7.	Gelsolin	00
11.8.	Uroplakin III	00
11.9.	CAIX	00
11.10.	HIF1A	00
11.11.	Others	00
12.	Combined biomarkers and nomograms	00
13.	Limitations of immunohistochemistry	00
14.	Summary	00
	Conflict of interest/funding	00
	Reviewers	00
	References	00
	Biography	00

Abstract

Bladder cancer is associated with high recurrence and mortality rates. These tumors show vast heterogeneity reflected by diverse morphologic manifestations and various molecular alterations associated with these disease phenotypes. Biomarkers that prospectively evaluate disease aggressiveness, progression risk, probability of recurrence and overall prognosis would improve patient care. Integration of molecular markers with conventional pathologic staging of bladder cancers may refine clinical decision making for the selection of adjuvant and salvage therapy. In the past decade, numerous bladder cancer biomarkers have been identified, including various tumor suppressor genes, oncogenes, growth factors, growth factor receptors, hormone receptors, proliferation and apoptosis markers, cell adhesion molecules, stromal factors, and oncoproteins. Recognition of two distinct pathways for urothelial carcinogenesis represents a major advance in the understanding and management of this disease. Nomograms for combining results from multiple biomarkers have been proposed to increase the accuracy of clinical predictions. The scope of this review is to summarize the major biomarker findings that may have translational and clinical implications. © 2013 Published by Elsevier Ireland Ltd.

Keywords: Urinary bladder; Urothelial carcinoma; Biomarkers; Prognosis; Tumorigenesis

1. Introduction

Urothelial carcinoma is the 5th most common cancer in industrialized countries, accounting for approximately 5%

of all cancers [1–3]. The associated risk factors for bladder cancer include tobacco smoking, aromatic amine exposure, arsenic exposure, chronic infection with *Schistosoma* species, radiation therapy, and exposure to alkylating agents [4,5].

Download English Version:

<https://daneshyari.com/en/article/6113665>

Download Persian Version:

<https://daneshyari.com/article/6113665>

[Daneshyari.com](https://daneshyari.com)